NasdaqGS:PRAXBiotechs
Praxis Precision Medicines (PRAX) Valuation After Analyst Upgrades And Key Breakthrough Therapy NDA Plans
Why Praxis Precision Medicines stock is back on investors’ radar
Praxis Precision Medicines (PRAX) has drawn fresh attention after multiple analysts expressed confidence in its lead drug candidates, alongside upcoming NDA submissions for ulixacaltamide and relutrigine, both with Breakthrough Therapy Designation.
See our latest analysis for Praxis Precision Medicines.
The recent 2.98% 1 day share price return and 18.55% 30 day share price return, on top of a 1 year total shareholder return of...